BACKGROUND: The objective of this study was to determine whether the 3-dose quadrivalent human papillomavirus (HPV) vaccine series (HPV-6, -11, -16, -18) is immunogenic and safe in young women infected with human immunodeficiency virus (HIV). METHODS: We enrolled 99 women aged 16-23 years in a phase 2, open-label, multicenter trial, conducted from 2008 to 2011 by the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Outcome measures were immunogenicity 4 weeks after dose 3, measured by (1) geometric mean titers (GMTs) and (2) seroconversion rates for HPV-6, -11, -16, and -18, among those seronegative and HPV DNA negative for each type. Immune responses were compared to those of a historical comparison group of HIV-negative women (n = 267) using univariate methods. Clinical and laboratory adverse events were assessed after each dose. RESULTS: The mean age of subjects was 21.4 years; 80% were non-Hispanic black, 69 were not taking antiretroviral therapy (ART), and 30 were taking ART. No differences in GMTs were noted among participants taking ART vs the comparison group, but GMTs were lower in participants not taking ART vs the comparison group for HPV-16 (2393 vs 3892 milli-Merck units per milliliter [mMU/mL], P = .012) and HPV-18 (463 vs 801 mMU/mL, P = .003). Seroconversion rates were 100% for HPV-6, -11, -16, and -18 among participants taking ART. Rates ranged from 92.3% (for HPV-18) to 100.0% (for HPV-6) among participants not taking ART. One severe adverse event (fatigue) was noted. CONCLUSIONS: In a sample of HIV-infected women who were HPV DNA and HPV seronegative, immune responses to HPV vaccination were generally robust and the vaccine was well tolerated.
BACKGROUND: The objective of this study was to determine whether the 3-dose quadrivalent human papillomavirus (HPV) vaccine series (HPV-6, -11, -16, -18) is immunogenic and safe in young women infected with human immunodeficiency virus (HIV). METHODS: We enrolled 99 women aged 16-23 years in a phase 2, open-label, multicenter trial, conducted from 2008 to 2011 by the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Outcome measures were immunogenicity 4 weeks after dose 3, measured by (1) geometric mean titers (GMTs) and (2) seroconversion rates for HPV-6, -11, -16, and -18, among those seronegative and HPV DNA negative for each type. Immune responses were compared to those of a historical comparison group of HIV-negative women (n = 267) using univariate methods. Clinical and laboratory adverse events were assessed after each dose. RESULTS: The mean age of subjects was 21.4 years; 80% were non-Hispanic black, 69 were not taking antiretroviral therapy (ART), and 30 were taking ART. No differences in GMTs were noted among participants taking ART vs the comparison group, but GMTs were lower in participants not taking ART vs the comparison group for HPV-16 (2393 vs 3892 milli-Merck units per milliliter [mMU/mL], P = .012) and HPV-18 (463 vs 801 mMU/mL, P = .003). Seroconversion rates were 100% for HPV-6, -11, -16, and -18 among participants taking ART. Rates ranged from 92.3% (for HPV-18) to 100.0% (for HPV-6) among participants not taking ART. One severe adverse event (fatigue) was noted. CONCLUSIONS: In a sample of HIV-infectedwomen who were HPV DNA and HPV seronegative, immune responses to HPV vaccination were generally robust and the vaccine was well tolerated.
Entities:
Keywords:
HIV infected; human papillomavirus; immunogenicity; safety; vaccine
Authors: Mark R Wallace; Carolyn J Brandt; Kenneth C Earhart; Barbara J Kuter; Anthony D Grosso; Hassan Lakkis; Sybil A Tasker Journal: Clin Infect Dis Date: 2004-09-24 Impact factor: 9.079
Authors: Alison G Abraham; Gypsyamber D'Souza; Yuezhou Jing; Stephen J Gange; Timothy R Sterling; Michael J Silverberg; Michael S Saag; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Richard D Moore; Marina B Klein; Mari M Kitahata; Gregory D Kirk; Robert S Hogg; Nancy A Hessol; James J Goedert; M John Gill; Kelly A Gebo; Joseph J Eron; Eric A Engels; Robert Dubrow; Heidi M Crane; John T Brooks; Ronald J Bosch; Howard D Strickler Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Stephen E Hawes; Cathy W Critchlow; Mame A Faye Niang; Mame B Diouf; Aissatou Diop; Papa Touré; Abdoul Aziz Kasse; Birama Dembele; Papa Salif Sow; Awa M Coll-Seck; Jane M Kuypers; Nancy B Kiviat Journal: J Infect Dis Date: 2003-07-23 Impact factor: 5.226
Authors: David Opalka; Charles E Lachman; Stefani A MacMullen; Kathrin U Jansen; Judith F Smith; Narendra Chirmule; Mark T Esser Journal: Clin Diagn Lab Immunol Date: 2003-01
Authors: W A O'Brien; K Grovit-Ferbas; A Namazi; S Ovcak-Derzic; H J Wang; J Park; C Yeramian; S H Mao; J A Zack Journal: Blood Date: 1995-08-01 Impact factor: 22.113
Authors: S I Staprans; B L Hamilton; S E Follansbee; T Elbeik; P Barbosa; R M Grant; M B Feinberg Journal: J Exp Med Date: 1995-12-01 Impact factor: 14.307
Authors: Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Julia M L Brotherton; Mark Jit; Patti E Gravitt; Marc Brisson; Aimée R Kreimer; Sara I Pai; Carole Fakhry; Joseph Monsonego; Silvia Franceschi Journal: Int J Cancer Date: 2016-03-22 Impact factor: 7.396
Authors: Lars Toft; Martin Tolstrup; Martin Müller; Peter Sehr; Jesper Bonde; Merete Storgaard; Lars Østergaard; Ole S Søgaard Journal: Hum Vaccin Immunother Date: 2014-02-19 Impact factor: 3.452
Authors: Eun Kyoung Park; Heerim Cho; Sun Hee Lee; Seung Geun Lee; Sang Yeup Lee; Ki Hyung Kim; Chang Hun Lee; Joo Seop Chung; Ihm Soo Kwak Journal: J Korean Med Sci Date: 2013-12-26 Impact factor: 2.153